Advances in the Combination Therapy of Targeted Anti-Cancer Drugs

Jie Yang; Yan Wu; Zhen Wu; Yong-Tao Cui; Xiao-Qi Peng

doi:doi:10.11648/j.sd.20160402.17

| Peer-Reviewed

Advances in the Combination Therapy of Targeted Anti-Cancer Drugs

Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng

Published in Science Discovery (Volume 4, Issue 2)

Received: 16 May 2016 Accepted: Published: 18 May 2016

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.

Published in	Science Discovery (Volume 4, Issue 2)
DOI	10.11648/j.sd.20160402.17
Page(s)	94-98
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cancer, Drug, Target, Combination Therapy

References

[1]	世卫组织预计到2030年癌症死亡人数可能翻番，生物学通报，2010年第45卷第03期，25。
[2]	胡胜等，癌症靶向药物的联合治疗，药品评价，2012年第9卷第21期，28-35。
[3]	Mendelsohn J, et al., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol., 2003, 21(14): 2787-2799.
[4]	王勐等，厄洛替尼与西妥昔单抗联合应用治疗吉非替尼耐药N S C L C 的疗效，中国肿瘤临床，2011年第38卷第24期，1505-1509。
[5]	韦玮等，西妥昔单抗联合厄洛替尼对人肝癌细胞的体外抑制作用，癌症，2008年第4期，386-392。
[6]	Miller KD, et al., Randomized phase Ⅲ trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer, J. Clin. Oncol., 2005, 23(4): 792-799.
[7]	Blackwell KL, et al., Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer, J. Clin. Oncol., 2010, 28(7): 1124-1130.
[8]	江秉华等，CN101332301A，2008年12月31日。
[9]	Wymann, M. P.,et al., Phosphoinositide 3-kinase signalling –which way to target Trends Pharmacol. Sci., 2003, 24(7): 366-376.
[10]	Cantley, C. C., et al., New insights into tumor suppression: PTEN suppresses tumorformation by restraining the phosphoinositide 3-kinaseyAKT pathway, Proc. Natl. Acad. Sci., 1999, 96: 4240-4245.
[11]	Engelman, J. A., Targeting PI3K signalling in cancer:opportunities, challenges andlimitations, Nature Reviews/Cancer, 2009, 9: 550-562.
[12]	Kozma, S. C. et al., Regulation of cell size in growth,development and human disease:PI3K, PKB and S6K, Bioessays, 2002, 24: 65-71.
[13]	Takeuchi H., et al., Synergistic Augmentation of Rapamycin-Induced Autophagyin Malignant Glioma Cells by Phosphatidylinositol3-Kinase/Protein Kinase B Inhibitors, Cancer Res., 2005, 65(8): 3336-3346.
[14]	Sun S.Y., et al., Activation of Akt and eIF4E Survival Pathways byRapamycin-Mediated Mammalian Target of RapamycinInhibition, Cancer Res., 2005, 65(16): 7052-7058.
[15]	BURSAVICH M.， et al.，WO2006044453A1, 2006年4月27日。
[16]	GARCIA E. C.，et al.，WO2010049481A1, 2010年5月6日。
[17]	FRITSCH C., et al.，WO2012148846 A1, 2012年11月1日。
[18]	GUO X., et al.，WO2012148540 A1, 2012年11月1日。
[19]	B. Markman, et al., Status of PI3K inhibition and biomarker development in cancer therapeutics, Ann. Oncol., 2009, 21(4): 683-691.
[20]	KLINGHOFFER R., et al.，WO2010120599 A2 2010年10月21日。
[21]	TAN J., et al.，WO2011084108 A1, 2011年7月14日。
[22]	LEE C. J., et al., WO2009036101A1, 2009年3月19日。
[23]	AFTAB D., et al., WO2008021389 A2，2008年2月21日。
[24]	FRITSCH C., et al., WO2010006225 A1, 2010年1月14日。
[25]	DUMBLE M., et al., WO2011038082 A1, 2011年3月31日。
[26]	DUMBLE M., et al., WO2011038085 A1, 2011年3月31日。
[27]	BEL V. M., et al., WO2011054620 A1, 2011年5月12日。
[28]	BIHONGNEU O. A., et al., WO2013037943 A1, 2013年3月21日。
[29]	GILMER T., et al., WO2011062930A1, 2011年5月26日。

Cite This Article

Plain Text BibTeX RIS

APA Style

Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. (2016). Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Science Discovery, 4(2), 94-98. https://doi.org/10.11648/j.sd.20160402.17

Copy | Download

ACS Style

Jie Yang; Yan Wu; Zhen Wu; Yong-Tao Cui; Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci. Discov. 2016, 4(2), 94-98. doi: 10.11648/j.sd.20160402.17

Copy | Download

AMA Style

Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci Discov. 2016;4(2):94-98. doi: 10.11648/j.sd.20160402.17

Copy | Download

@article{10.11648/j.sd.20160402.17,
  author = {Jie Yang and Yan Wu and Zhen Wu and Yong-Tao Cui and Xiao-Qi Peng},
  title = {Advances in the Combination Therapy of Targeted Anti-Cancer Drugs},
  journal = {Science Discovery},
  volume = {4},
  number = {2},
  pages = {94-98},
  doi = {10.11648/j.sd.20160402.17},
  url = {https://doi.org/10.11648/j.sd.20160402.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20160402.17},
  abstract = {The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.},
 year = {2016}
}

Copy | Download

TY  - JOUR
T1  - Advances in the Combination Therapy of Targeted Anti-Cancer Drugs
AU  - Jie Yang
AU  - Yan Wu
AU  - Zhen Wu
AU  - Yong-Tao Cui
AU  - Xiao-Qi Peng
Y1  - 2016/05/18
PY  - 2016
N1  - https://doi.org/10.11648/j.sd.20160402.17
DO  - 10.11648/j.sd.20160402.17
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 94
EP  - 98
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20160402.17
AB  - The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.
VL  - 4
IS  - 2
ER  -

Copy | Download

Author Information

Jie Yang

Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China
Yan Wu

Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China
Zhen Wu

Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China
Yong-Tao Cui

Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China
Xiao-Qi Peng

Patent Examination Cooperation Center of the Patent Office, SIPO, Beijing, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. (2016). Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Science Discovery, 4(2), 94-98. https://doi.org/10.11648/j.sd.20160402.17

Copy | Download

ACS Style

Jie Yang; Yan Wu; Zhen Wu; Yong-Tao Cui; Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci. Discov. 2016, 4(2), 94-98. doi: 10.11648/j.sd.20160402.17

Copy | Download

AMA Style

Jie Yang, Yan Wu, Zhen Wu, Yong-Tao Cui, Xiao-Qi Peng. Advances in the Combination Therapy of Targeted Anti-Cancer Drugs. Sci Discov. 2016;4(2):94-98. doi: 10.11648/j.sd.20160402.17

Copy | Download

@article{10.11648/j.sd.20160402.17,
  author = {Jie Yang and Yan Wu and Zhen Wu and Yong-Tao Cui and Xiao-Qi Peng},
  title = {Advances in the Combination Therapy of Targeted Anti-Cancer Drugs},
  journal = {Science Discovery},
  volume = {4},
  number = {2},
  pages = {94-98},
  doi = {10.11648/j.sd.20160402.17},
  url = {https://doi.org/10.11648/j.sd.20160402.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20160402.17},
  abstract = {The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.},
 year = {2016}
}

Copy | Download

TY  - JOUR
T1  - Advances in the Combination Therapy of Targeted Anti-Cancer Drugs
AU  - Jie Yang
AU  - Yan Wu
AU  - Zhen Wu
AU  - Yong-Tao Cui
AU  - Xiao-Qi Peng
Y1  - 2016/05/18
PY  - 2016
N1  - https://doi.org/10.11648/j.sd.20160402.17
DO  - 10.11648/j.sd.20160402.17
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 94
EP  - 98
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20160402.17
AB  - The combination therapy of targeted anti-cancer drugs is important in the research of anti-cancer drugs. This articleintroduced the status of combination therapy of the same targeted and different targeted anti-cancer drugs, and analyzed the challenges and difficulties. In order to provide reference basis for development of combination therapy technique of targeted anti-cancer drugs in China.
VL  - 4
IS  - 2
ER  -

Copy | Download